Archives of Medical Research
Volume 40, Issue 6 , Pages 435-442 , August 2009

Host Factors in HPV-related Carcinogenesis: Cellular Mechanisms Controlling HPV Infections

Received 25 May 2009 ,Accepted 1 June 2009.

References 

  1. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907
  2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–350
  3. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89:213–228
  4. zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet. 1986;2:489–491
  5. Chow LT, Duffy AA, Wang HK, et al. A highly efficient system to produce infectious human papillomavirus: elucidation of natural virus-host interactions. Cell Cycle. 2009;8:1319–1323
  6. Wang HK, Duffy AA, Broker TR, et al. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 2009;23:181–194
  7. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology. 2009;384:375–379
  8. Selinka HC, Florin L, Patel HD, et al. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol. 2007;81:10970–10980
  9. Schelhaas M, Ewers H, Rajamaki ML, et al. Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog. 2008;4:e1000148
  10. Day PM, Lowy DR, Schiller JT. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology. 2003;307:1–11
  11. Smith JL, Campos SK, Ozbun MA. Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol. 2007;81:9922–9931
  12. Smith JL, Campos SK, Wandinger-Ness A, et al. Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J Virol. 2008;82:9505–9512
  13. Stoler MH, Broker TR. In situ hybridization detection of human papillomavirus DNAs and messenger RNAs in genital condylomas and a cervical carcinoma. Hum Pathol. 1986;17:1250–1258
  14. Stoler MH, Wolinsky SM, Whitbeck A, et al. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology. 1989;172:331–340
  15. Stoler MH, Rhodes CR, Whitbeck A, et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol. 1992;23:117–128
  16. Cameron JE, Hagensee ME. Human papillomavirus infection and disease in the HIV+ individual. Cancer Treat Res. 2007;133:185–213
  17. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr. 2003;52–56
  18. Orth G, Favre M, Majewski S, et al. Epidermodysplasia verruciformis defines a subset of cutaneous human papillomaviruses. J Virol. 2001;75:4952–4953
  19. Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet. 2002;32:579–581
  20. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers. 2007;23:297–313
  21. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68:362–372
  22. Middleton K, Peh W, Southern S, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol. 2003;77:10186–10201
  23. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006;16:83–97
  24. Steger G, Corbach S. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J Virol. 1997;71:50–58
  25. Kruppel U, Muller-Schiffmann A, Baldus SE, et al. E2 and the co-activator p300 can cooperate in activation of the human papillomavirus type 16 early promoter. Virology. 2008;377:151–159
  26. You J, Croyle JL, Nishimura A, et al. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell. 2004;117:349–360
  27. Cheng S, Schmidt-Grimminger DC, Murant T, et al. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 1995;9:2335–2349
  28. Jia R, Liu X, Tao M, et al. Control of the papillomavirus early-to-late switch by differentially expressed SRp20. J Virol. 2009;83:167–180
  29. Stanley MA. Immunobiology of papillomavirus infections. J Reprod Immunol. 2001;52:45–59
  30. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005;97:577–586
  31. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004;109:157–162
  32. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690–698
  33. Kadaja M, Isok-Paas H, Laos T, et al. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog. 2009;5:e1000397
  34. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?. J Pathol. 2007;212:356–367
  35. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11–22
  36. Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999;59:6132–6136
  37. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68:307–313
  38. Melsheimer P, Vinokurova S, Wentzensen N, et al. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin. Cancer Res. 2004;10:3059–3063
  39. Arias-Pulido H, Peyton CL, Joste NE, et al. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol. 2006;44:1755–1762
  40. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130:223–233
  41. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA. 1996;93:4350–4354
  42. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741–1748
  43. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002;38:2229–2242
  44. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers. 2007;23:315–330
  45. Schrump DS, Chen GA, Consuli U, et al. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther. 1996;3:357–364
  46. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276–284
  47. Ballestar E, Esteller M. SnapShot: the human DNA methylome in health and disease. Cell. 2008;135:1144
  48. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature. 2007;447:433–440
  49. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669–681
  50. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008;454:766–770
  51. Feinberg AP. An epigenetic approach to cancer etiology. Cancer J. 2007;13:70–74
  52. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31:89–97
  53. Badal S, Badal V, Calleja-Macias IE, et al. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology. 2004;324:483–492
  54. Badal V, Chuang LS, Tan EH, et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol. 2003;77:6227–6234
  55. Bhattacharjee B, Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology. 2006;354:280–285
  56. Fernandez AF, Rosales C, Lopez-Nieva P, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009;19:438–451
  57. Kalantari M, Calleja-Macias IE, Tewari D, et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol. 2004;78:12762–12772
  58. Kalantari M, Lee D, Calleja-Macias IE, et al. Effects of cellular differentiation, chromosomal integration and 5-aza-2′-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines. Virology. 2008;374:292–303
  59. Turan T, Kalantari M, Calleja-Macias IE, et al. Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?. Virology. 2006;349:175–183
  60. Turan T, Kalantari M, Cuschieri K, et al. High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology. 2007;361:185–193
  61. Kim K, Garner-Hamrick PA, Fisher C, et al. Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol. 2003;77:12450–12459
  62. Doerfler W. In pursuit of the first recognized epigenetic signal–DNA methylation: a 1976 to 2008 synopsis. Epigenetics. 2008;3:125–133
  63. Danos O, Katinka M, Yaniv M. Molecular cloning, refined physical map and heterogeneity of methylation sites of papilloma virus type 1a DNA. Eur J Biochem. 1980;109:457–461

PII: S0188-4409(09)00093-9

doi: 10.1016/j.arcmed.2009.06.002

Archives of Medical Research
Volume 40, Issue 6 , Pages 435-442 , August 2009

Article Tools

* Image Usage & Resolution